Form 13-F position report

BIOGEN INC

Reported by VANGUARD GROUP INC

BIIB CUSIP 09062X103 Manager CIK 0000102909

Reported 14,407,330 shares, up 2,218,744 (18.2%) from the prior quarter.

Reported value 19.0%; share count 18.2% vs. the prior quarter.

Added
% of reported 13F value 0.08% This manager · Q4 2023
Shares 14,407,330 Quarter-end amount reported
Reported value $3,728,184,783 Fair value at quarter end
Consecutive quarters held 43 Through Q4 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 3316059000
2021-06-30 4069827000
2021-09-30 3308684000
2021-12-31 2768029000
2022-03-31 2468356000
2022-06-30 2418733000
2022-09-30 3181298000
2022-12-31 3316566441
2023-03-31 3380194766
2023-06-30 3474154794
2023-09-30 3132588488
2023-12-31 3728184783
2024-03-31 3573074920
2024-06-30 3848249787
2024-09-30 3232961797
2024-12-31 2561237965
2025-03-31 2330773689
2025-06-30 2171532858
2025-09-30 2421876038
2025-12-31 3070513721

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for BIOGEN INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 17,447,092 +157,857 (0.9%) 0.04% $3,070,513,721 2026-01-29
Q3 2025 Reduced 17,289,235 -1,416 (0.0%) 0.04% $2,421,876,038 2025-11-07
Q2 2025 Added 17,290,651 +257,812 (1.5%) 0.04% $2,171,532,858 2025-08-11
Q1 2025 Added 17,032,839 +283,964 (1.7%) 0.04% $2,330,773,689 2025-05-09
Q4 2024 Added 16,748,875 +70,368 (0.4%) 0.04% $2,561,237,965 2025-02-11
Q3 2024 Added 16,678,507 +78,344 (0.5%) 0.06% $3,232,961,797 2024-11-13
Q2 2024 Added 16,600,163 +29,765 (0.2%) 0.07% $3,848,249,787 2024-08-13
Q1 2024 Added 16,570,398 +2,163,068 (15.0%) 0.07% $3,573,074,920 2024-05-10
Q4 2023 Added 14,407,330 +2,218,744 (18.2%) 0.08% $3,728,184,783 2024-02-14
Q3 2023 Reduced 12,188,586 -7,850 (-0.1%) 0.08% $3,132,588,488 2023-11-14
Q2 2023 Added 12,196,436 +38,774 (0.3%) 0.08% $3,474,154,794 2023-08-14
Q1 2023 Added 12,157,662 +181,039 (1.5%) 0.09% $3,380,194,766 2023-05-15
Q4 2022 Added 11,976,623 +61,650 (0.5%) 0.09% $3,316,566,441 2023-02-10
Q3 2022 Added 11,914,973 +54,951 (0.5%) 0.09% $3,181,298,000 2022-11-14
Q2 2022 Added 11,860,022 +139,438 (1.2%) 0.07% $2,418,733,000 2022-08-12
Q1 2022 Added 11,720,584 +183,285 (1.6%) 0.06% $2,468,356,000 2022-05-13
Q4 2021 Reduced 11,537,299 -154,577 (-1.3%) 0.06% $2,768,029,000 2022-02-14
Q3 2021 Reduced 11,691,876 -61,457 (-0.5%) 0.08% $3,308,684,000 2021-11-12
Q2 2021 Reduced 11,753,333 -100,325 (-0.8%) 0.1% $4,069,827,000 2021-08-13
Q1 2021 Reduced 11,853,658 -42,852 (-0.4%) 0.09% $3,316,059,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1084 managers reported BIOGEN INC for Q4 2023.

Managers reporting BIOGEN INC in Q4 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PRIMECAP MANAGEMENT CO CA Added 16,264,481 +251,915 3.33% $4,208,759,748 43 qtrs
VANGUARD GROUP INC This report Added 14,407,330 +2,218,744 0.08% $3,728,184,783 43 qtrs
BlackRock Inc Added 14,246,658 +272,071 0.09% $3,686,607,689 43 qtrs
STATE STREET CORPORATION Added 6,945,665 +80,011 0.09% $1,797,329,732 43 qtrs
T Rowe Price Investment Management Inc Added 5,357,326 +602,335 0.9% $1,386,316,000 3 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 5,324,396 -49,914 0.26% $1,377,793,953 43 qtrs
JPMorgan Chase & Co Added 5,072,640 +86,888 0.13% $1,312,647,270 43 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 3,309,317 +72,430 0.09% $854,137,923 43 qtrs
Invesco Ltd Added 1,814,666 +633,292 0.11% $469,581,120 43 qtrs
Clearbridge Investments LLC Reduced 1,679,302 -143,880 0.37% $434,552,981 43 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2023
Filed
February 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
451
Shared
180,828
None
14,226,051

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.